Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...

The healthcare leader posted adjusted earnings per share of $1.26 for the quarter, slightly above the consensus estimate of ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

The Details: Kinder Morgan reported quarterly earnings of 28 cents per share, which beat the analyst consensus estimate of 27 ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...

Merit Medical Systems will announce Q2 2025 financial results on July 30, followed by an investor conference call.

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader market significantly in Q2 2025. With a 12.12% weighting in the S&P 500, ...

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025.

Moderna’s new influenza vaccine, based on the same mRNA technology used in its COVID-19 vaccine, showed promising results in a major trial.

TUESDAY, July 1, 2025 (HealthDay News) — Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...